Efficacy and delivery strategies of the dual Rac/Cdc42 inhibitor MBQ-167 in HER2 overexpressing breast cancer

• DOI: 10.1016/j.tranon.2024.101928
• Publication Date: 2024-03-15T07:25:14Z
• Authors: Luis E. Velázquez...; Michael Rivera-Ro...; Annelis O. Sánche...; Pablo E. Vivas-Mejía; Miciely Aponte-Reyes; Ailed M. Cruz-Col...; Nilmary Grafals-Ruiz; Stephanie Dorta-E...; Eliud Hernández-O...; Cornelis P Vlaar; Suranganie Dharma...
• Keywords: CDC42; SKBR3

Trastuzumab and trastuzumab-based treatments are the standard of care for breast cancer patients who overexpress human epidermal growth factor receptor 2 (HER2). However, often develop resistance to trastuzumab via signaling from alternative receptors that converge activate guanine nucleotide exchange factors (GEFs) in turn Rho GTPases Rac Cdc42. Since Cdc42 have been implicated high tumor grade therapy resistance, inhibiting activity is a rational strategy overcome HER2-targeted resistance. Therefore, our group developed MBQ-167, dual Rac/Cdc42 inhibitor with IC